File: '\\swfile\EmailIn\20241224 102211 Attachment Treatment.com AI Inc. - News Release Announcing Conversion of Special Warrants and filing of prospectus supplementFINAL.docx'

LEGAL_45643392.1

Treatment

TREATMENT.COM AI INC. ANNOUNCES AUTOMATIC CONVERSION OF SPECIAL WARRANTS

Vancouver, British Columbia, December 24, 2024 - Treatment.com AI Inc. (the "Company" or "Treatment") (CSE: TRUE; OTC: TREIF; FFA: 939) announces that it has filed a prospectus supplement dated December 20, 2024 (the "Prospectus Supplement") to its short form base shelf prospectus dated June 24, 2024 (the "Shelf Prospectus") to qualify the distribution of securities underlying 2,138,766 special warrants (the "Special Warrants") issued by the Company on October 25, 2024 (the "Offering").

The Prospectus Supplement qualifies the distribution of 2,138,766 common shares (each a "Common Share") and 1,069,383 common share purchase warrants (each a "Warrant") comprising the units of the Company issuable on the exercise or deemed exercise of the Special Warrants in the Provinces of British Columbia, Alberta, Manitoba and Ontario. Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $1.00 until 5:00 p.m. (Pacific Time) for a period of 24 months.

The Special Warrants will be deemed to be converted into Common Shares and Warrants on December 27, 2024. No action is required on the part of any holder of Special Warrants to convert their Special Warrants into underlying securities.

The qualification rights of holders of Special Warrants are further described in the Prospectus Supplement and the Shelf Prospectus, which can be found under the Company's profile on SEDAR+ at www.sedarplus.ca.

Access to the Shelf Prospectus and the Prospectus Supplement, and any amendment to the documents, is provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Shelf Prospectus and the Prospectus Supplement are accessible on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Prospectus Supplement, the corresponding Shelf Prospectus and any amendment to the documents may be obtained, without charge, from the Company by email at info@treatment.com and by providing the contact with an email address or address, as applicable.

The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment's products and services: www.treatment.com or email: info@treatment.com

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

ehamza@treatment.com

For media inquiries, contact: media@treatment.com

Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955

Cautionary Statement

This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, future plans and objectives of Treatment, are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.